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 infection [1]. In 2013, there were over 2.3 million con-
firmed cases of malaria, accounting for more than 20% of 
outpatient visits, 19% of hospital admissions and 3–5% of 
hospital deaths [2]. However, there have been important 
reductions in malaria prevalence in recent years. Between 
2010 and 2015, national data reveal malaria prevalence 
in children aged 6 months to 14 years fell from 11 to 8% 
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The malaria testing and treatment 
landscape in Kenya: results from a nationally 
representative survey among the public 
and private sector in 2016
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Abstract 
Background: Since 2004, Kenya’s national malaria treatment guidelines have stipulated artemisinin-based combina-
tion therapy (ACT) as first-line treatment for uncomplicated malaria, and since 2014, confirmatory diagnosis of malaria 
in all cases before treatment has been recommended. A number of strategies to support national guidelines have 
been implemented in the public and private sectors in recent years. A nationally-representative malaria outlet survey, 
implemented across four epidemiological zones, was conducted between June and August 2016 to provide practical 
evidence to inform strategies and policies in Kenya towards achieving national malaria control goals.
Results: A total of 17,852 outlets were screened and 2271 outlets were eligible and interviewed. 78.3% of all 
screened public health facilities stocked both malaria diagnostic testing and quality-assured ACT (QAACT). Sulfadox-
ine–pyrimethamine (SP) for intermittent preventive treatment in pregnancy was available in 70% of public health 
facilities in endemic areas where it is recommended for treatment. SP was rarely found in the public sector outside of 
the endemic areas (< 0.5%). The anti-malaria stocking private sector had lower levels of QAACT (46.7%) and malaria 
blood testing (20.8%) availability but accounted for majority of anti-malarial distribution (70.6% of the national market 
share). More than 40% of anti-malarials were distributed by unregistered pharmacies (37.3%) and general retailers 
(7.1%). QAACT accounted for 58.2% of the total anti-malarial market share, while market share for non-QAACT was 
15.8% and for SP, 24.8%. In endemic areas, 74.9% of anti-malarials distributed were QAACT. Elsewhere, QAACT market 
share was 49.4% in the endemic-prone areas, 33.2% in seasonal-transmission areas and 37.9% in low-risk areas.
Conclusion: Although public sector availability of QAACT and malaria diagnosis is relatively high, there is a gap in 
availability of both testing and treatment that must be addressed. The private sector in Kenya, where the majority of 
anti-malarials are distributed, is also critical for achieving universal coverage with appropriate malaria case manage-
ment. There is need for a renewed commitment and effective strategies to ensure access to affordable QAACT and 
confirmatory testing in the private sector, and should consider how to address malaria case management among 
informal providers responsible for a substantial proportion of the anti-malarial market share.
Keywords: Malaria control case management, Anti-malarial, ACT, Private sector, Public sector, Malaria diagnosis, Kenya
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Background
Malaria is the leading cause of morbidity and mortal-
ity in Kenya, with over 70% of the population at risk of 
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respectively. Furthermore, from 2011 to 2015 the sus-
pected outpatient malaria cases, as a proportion of the 
outpatient department cases, declined from over 35 to 
15% [3]. However, regional variations are apparent, and 
analysis has shown a trend of increased prevalence of 
Plasmodium falciparum in the coastal-endemic area over 
the same period [3, 4].
Given the variability in malaria transmission through-
out the country, the Kenya National Malaria Control 
Programme has defined epidemiological zones based on 
malaria risk and burden [5]. These malaria epidemiologi-
cal zones are largely defined by altitude, rainfall patterns 
and temperature. They include: endemic areas around 
Lake Victoria in western Kenya and in the coastal region; 
highland epidemic-prone areas of western Kenya and the 
Rift Valley region; seasonal-transmission areas, which are 
the arid and semi-arid areas of the northern and south 
eastern parts of the country; and low-risk areas in the 
central highlands of Kenya including Nairobi [5]. These 
epidemiological zones are used to guide the implemen-
tation of malaria control interventions, including inter-
mittent preventive treatment in pregnancy (IPTp) and 
community case management, which are both focused in 
endemic areas.
Following a recognition that sulfadoxine–pyrimeth-
amine (SP) was failing, in 2004 the National Malaria Con-
trol Programme adopted artemether–lumefantrine (AL) 
as the first-line treatment for uncomplicated malaria, 
with the change being widely implemented from 2006 
onwards [6]. The national malaria control guidelines, rec-
ommend dihydroartemisinin-piperaquine as the second-
line treatment for uncomplicated malaria in Kenya. The 
treatment recommendation for severe malaria is paren-
teral artesunate, while treatment with parenteral qui-
nine is permitted in absence of artesunate. Patients with 
severe malaria should be referred to higher levels of care. 
SP is recommended for IPTp only in the malaria endemic 
zones. The 2014 Kenya national malaria control guide-
lines recommend confirmatory diagnosis of malaria in all 
age-groups of patients in all epidemiological settings [7]. 
This was a departure from the previous guidelines that 
recommended presumptive treatment.
National malaria control strategies 
and interventions for case management
Several strategies have been implemented to ensure 
access to quality case management services and com-
modities. Between 2010 and 2013, Kenya and other six 
countries (Ghana, Madagascar, Niger, Nigeria, Tanza-
nia [including Zanzibar] and Uganda) participated in 
the Affordable Medicines Facility for malaria (AMFm). 
The AMFm provided quality-assured ACT (QAACT) 
to wholesalers at a heavily-subsidized cost with the 
objective of increasing access to affordable ACT in 
both the public and private sector [8]. The packaging of 
AMFm-subsidized QAACT was marked with a distinc-
tive green leaf logo for easy identification. By the end 
of 2011, approximately 14.35 million co-paid QAACT 
treatments were delivered to Kenya’s public sector and 
14.1 million to the private sector [9]. The AMFm inde-
pendent evaluation reported significant improvements in 
availability, price, and relative market share of QAACT in 
Kenya, and especially in the private sector [8, 10].
Building on the successes of the AMFm, the Global 
Fund introduced a new funding model, known as the 
co-payment mechanism (CPM), to support private sec-
tor access to QAACT medicines. The CPM focused 
exclusively on the private sector supply of QAACT given 
that the independent evaluation showed that the AMFm 
had greater impact on the supply of QAACT in the pri-
vate than compared to the public sector [10]. However, 
the public sector continued to receive subsidized ACT 
through an alternative Global Fund mechanism. Dur-
ing the CPM, QAACTs in this sector were not marked 
with the green leaf logo. While substantial resources 
were provided by donor communities for procurement 
of subsidized QAACT in Kenya for the period between 
2013 and 2015, resources were not at their peak as dur-
ing the AMFm period. In 2015, only 6.85 million treat-
ments were delivered to the private sector through the 
CPM. The ACT subsidy was also decreased to wholesal-
ers from 90 to 70% for all pack sizes [9], lending to a rec-
ommended retail price of $1.00 to the consumer, for both 
children and adults. Finally, while several mass commu-
nication activities were implemented to increase demand 
and consumer awareness of QAACT, these were discon-
tinued in mid-2015 [9].
In addition to the AMFm and CPM, other strate-
gies have been implemented to increase availability and 
demand for rapid diagnostic tests (RDTs) [5, 11]. In the 
private sector, this was supported by changing national 
policy to allow point-of-service testing beyond private 
hospitals and large private for-profit health facilities to 
registered pharmacies. In the public sector, RDTs were 
permitted and supplied to lower-level facilities, including 
community health workers (CHW) operating in malaria 
endemic areas.
Data on the anti-malarial and malaria diagnostic 
markets in Kenya provide an important benchmark 
to measure the extent to which malaria case manage-
ment services are available and are aligned with national 
malaria control guidelines. The ACTwatch project, a 
multi-country research project that was launched in 
2008, provides timely, relevant and high quality evi-
dence for this purpose [12]. The objective of this paper 
is to provide practical evidence to inform strategies and 
Page 3 of 13ACTwatch Group et al. Malar J  (2017) 16:494 
policies in Kenya towards achieving national malaria 
control goals, by describing the total market for malaria 
medicines and diagnostics at national level. This paper 
presents data from the recently conducted outlet survey 
in 2016.
Methods
Design
A nationally-representative, cross-sectional quantitative 
survey was conducted among outlets with potential to 
stock anti-malarials or malaria diagnosis. All potential 
public and private sector outlets were included in the 
survey. The public sector included all tiers of the health 
care system (hospitals, health centers, dispensaries, clin-
ics and CHWs) owned by government or affiliated with 
the not-for profit organizations such as non-governmen-
tal and faith-based institutions. Outlets surveyed in the 
private sector included, private for-profit health facilities 
(hospitals, nursing homes/medical centers and clinics), 
pharmacies and chemists (registered and unregistered) 
and general retailers selling fast-moving consumer goods. 
Table  1 provides an additional description of the outlet 
types.
Sampling
The 2016 survey was stratified to deliver estimates for 
each of the aforementioned malaria epidemiologi-
cal zones in Kenya. Clusters were selected from the 
four malaria epidemiological zones and defined as (1) 
endemic areas, (2) epidemic-prone areas, (3) seasonal-
transmission areas, and (4) low-risk areas. Considering 
that updated and comprehensive lists of all potentially 
eligible outlets were not routinely available at both 
national and sub-national levels, a cluster sampling 
approach with an outlet census was used to identify 
outlets for inclusion. A cluster was defined as an admin-
istrative unit ideally with a population of 10,000–15,000 
inhabitants and this corresponded with a “location”. 
Using 2009 Kenya Population and Housing Census 
[13], a national sampling framework was constructed 
and survey clusters or locations were selected using 
the technique of probability proportional to population 
size.
The survey was powered to detect a minimum of a 
10-percentage point change in availability of QAACT 
medicines within each strata at the 5% significance level 
with 80% power. The number of study clusters was cal-
culated for each strata based on the required number 
of anti-malarial stocking outlets, assumptions about 
the number of anti-malarial stocking outlets per cluster 
and information from previous survey rounds including 
anti-malarial and QAACT availability, outlet density per 
cluster, and design effect. A total of 84 locations were 
sampled, this included 17 endemic locations, 22 epi-
demic-prone locations, 28 seasonal-transmission loca-
tions, and 17 low-risk locations. Within each sampled 
location, all outlets with the potential to provide anti-
malarials or diagnostic testing services to patients or cli-
ents were screened for eligibility. In all sampled locations, 
the census boundary was extended to the higher admin-
istrative unit, the “division”, to allow for over sampling of 
public health facilities that are relatively uncommon at 
the location level but important outlet type in health ser-
vice provision.
Training and fieldwork
Data were collected between 7th June and 17th August, 
2016 by 14 data collection teams. All fieldworkers 
attended a standardized training that consisted of class-
room presentations, exercises and role plays as well as 
a field exercise. Additional training was provided for 
supervisors and quality-controllers that focused on field 
monitoring, verification visits, and census procedures. 
Data collection teams were provided with a list of sam-
pled locations and official maps that illustrated their 
administrative boundaries. In each sampled location, 
fieldworkers conducted a systematic and full enumera-
tion of all outlets.
Table 1 Outlet descriptions
Public health facilities Tertiary referral hospital, secondary referral hospitals, primary referral hospitals, health centers and dispensaries. 
There are over 3000 Ministry of Health public health facilities in Kenya
Community health worker Community-based health workers, including community health volunteers
Private for-profit health facilities Private hospitals, clinics, dispensaries, and diagnostic laboratories. There are over 3100 registered private for-profit 
health facilities in Kenya
Registered pharmacies/chemists Pharmacies are licensed and regulated by the Pharmacy and Poisons Board and include Pharmacist Premises. By 
2014, there were over 3900 registered Pharmacies in Kenya
Unregistered pharmacies/chemists Small businesses that are not registered with the Pharmacy and Poisons Board, but sell various classes of prescrip-
tion and over-the-counter medicine at commercial prices
General retailers Supermarkets, duka, kiosks, market stalls, and petrol stations
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Measures
Data were collected using a standardized ACTwatch 
outlet survey questionnaire and key informant inter-
views. Using the outlet survey questionnaire, the primary 
provider/owner of each potential outlet was invited to 
participate in the study and screening questions were 
administered to assess eligibility. Consenting providers 
were asked to show the interviewer all anti-malarials and 
malaria RDTs currently available. An anti-malarial audit 
sheet was completed to capture information for each 
unique anti-malarial product in the outlet, including for-
mulation, brand name, active ingredients and strengths, 
package size, manufacturer and country of manufacture. 
Providers were asked to report the retail and wholesale 
cost for each medicine, as well as the amount distrib-
uted to individual consumers in the last week. Similarly, 
among the outlets found stocking malaria RDTs, an audit 
was completed to record information such as brand 
name, manufacturer, country of manufacturer, reported 
retail selling price and number of tests conducted or sold 
in the last 7 days for each of unique RDT product. Finally, 
a provider module was administered to assess provider’s 
knowledge and reported practices on malaria case-man-
agement policy recommendations. Outlet survey data 
were captured using Android phones fitted with custom-
ized forms created using DroidDB (© SYWARE, Inc., 
Cambridge, MA, USA). Interviews were conducted in 
local language using questionnaires that were translated 
from English to Swahili language and back to English to 
confirm translations.
Protection of human subjects
The outlet survey protocol received ethical approval from 
Kenyatta National Hospital–University of Nairobi Eth-
ics & Research Committee (Reference Number KNH-
ERC/A/145). Provider interviews and product audits 
were completed only after administration of a standard 
informed consent form and provider consent to partici-
pate in the study. Standard measures were employed to 
maintain respondent confidentiality and anonymity, such 
as ensuring privacy during interviews, secure storage of 
completed questionnaires, and preventing any sharing of 
data between outlets. Providers had the option to end the 
interview at any point during the study.
Data analysis
Data were analysed using Stata version 13.1 (StataCorp 
College Station, Texas, USA). Standard indicators were 
constructed according to definitions applied across the 
ACTwatch project and have been described elsewhere 
[12, 14]. Descriptive analysis was undertaken, all point 
estimates and 95% confidence intervals were weighted 
to provide national estimates and calculated using Stata 
survey setting procedures to account for the complex 
clustered and stratified sampling strategy. The sampling 
weights were calculated as the inverse of the probability 
of cluster selection. Data were presented according to the 
four strata as well as by outlet types.
Definitions
According to information on drug formulation, active 
pharmaceutical ingredients and strengths, anti-malarials 
were classified as non-artemisinin therapies, artemisinin 
monotherapies and ACTs. ACT medicines were further 
classified as either QAACT or non-quality-assured ACT 
(non-QAACT). QAACT was defined as ACT medicines 
that had World Health Organization prequalification sta-
tus, ACT medicines in compliance with the Global Fund 
quality assurance policy, or ACT medicines granted regu-
latory approval by the European Medicines Agency. ACT 
medicines that did not meet requirements for QAACTs 
were categorized as non-QAACTs.
Availability of any anti-malarial was calculated with all 
screened outlets as the denominator. In the public sec-
tor, the availability of specific types of anti-malarials was 
calculated using the denominator of all screened outlets 
given that anti-malarials should be available at all public 
health facilities and among CHWs. Availability of spe-
cific anti-malarial categories in the private sector was 
calculated using the total number of private sector out-
lets stocking any anti-malarial as the denominator. Outlet 
“readiness” for malaria case management was defined as 
the extent to which an outlet had QAACT and malaria 
testing available.
This paper also presents market share and price indi-
cators among different classes of anti-malarials. The 
measure of adult equivalent treatment dose (AETD) was 
deployed to analyse market share and price to allow for 
meaningful comparisons between anti-malarials with dif-
ferent treatment courses. The AETD was defined as the 
amount of active ingredient required to treat an adult 
weighing 60  kg according to World Health Organiza-
tion treatment guidelines [15]. Provider reports on the 
amount of the drug sold or distributed during the week 
preceding the survey were used to calculate sales or dis-
tribution volume according to type of anti-malarial. All 
dosage formulations were included in the sales or distri-
bution volume calculation to provide a complete assess-
ment of anti-malarial market share to the consumer or 
patient. Volumes were therefore the number of AETDs 
sold or distributed by a provider in the 7 days prior to the 
survey. Additional public health facilities sampled as part 
of over-sampling for these outlet types were not included 
in market share calculations.
Price data were collected in Kenya Shillings and con-
verted to United States Dollar based on official exchange 
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rates for the data collection period. Anti-malarial price 
indicators are expressed as median unit cost for one 
AETD to allow for comparability between classes of anti-
malarials. Only tablet formulations are reported due to 
the differences in unit costs for tablet and non-tablet for-
mulations. The interquartile range (IQR) was calculated 
to demonstrate price dispersion.
Provider perceptions regarding the most effective first-
line treatment was assessed by administering questions 
to the senior most provider at all anti-malarial-stocking 
outlets. Providers were asked to describe what medi-
cine they believed was the most effective treatment for 
uncomplicated malaria in a child and in an adult.
Results
Sample size description
A total of 17,852 outlets were screened for availability 
of anti-malarials and/or malaria blood testing services. 
Of screened outlets, 2291 were stocking anti-malarials 
or testing on the day of the survey or within the past 
3  months, and 2271 were subsequently interviewed. A 
total of 1917 eligible and interviewed outlets were stock-
ing anti-malarials on the day of the survey, 293 report-
edly stocked anti-malarial(s) within the past 3  months 
while 61 were found stocking malaria diagnostics with-
out anti-malarial products. A total of 6716 anti-malarial 
medicines and 846 RDT products were audited (Addi-
tional file 1).
Public sector availability
Table  2 summarizes the availability of anti-malarials 
and diagnostics among the screened public sector out-
lets on the day of survey. Availability of any anti-malar-
ial medicine was 91.8 and 2.4% among CHW, and this 
was highest in the endemic areas (99.0%) and lowest in 
the low-risk areas (81.0%). Among the screened out-
lets, 87.1% of public health facilities had QAACT medi-
cines available and this varied by epidemiological zone: 
endemic areas (92.2%), endemic-prone areas (93.5%), 
seasonal-transmission areas (87.5%) and low-risk areas 
(77.0%). Public health facility availability of weight spe-
cific QA AL was variable: 66.4% for 6 tablet-pack QA 
AL, 63.3% for 12 tablet-pack QA AL, 37.0% for 18 tablet-
pack QA AL and 72.7% for adult tablet-pack of QA AL 
(Additional file 2). Availability of non-QAACT medicines 
among all screened public health facilities was 12.3% and 
highest in the low-risk areas (17.8%). Overall availabil-
ity of SP among the screened public health facilities was 
17.6%, but this varied by epidemiological zone, where 
availability was 70.0% in endemic areas and less than 1% 
across all other epidemiological zones. Of all screened 
public health facilities, 46.0% stocked artesunate injec-
tion and this varied by epidemiological zone: endemic 
areas (59.8%), endemic-prone areas (63.9%), seasonal-
transmission areas (48.9%) and low-risk areas (16.0%).
Of all screened public health facilities, 86.4% had 
capacity for malaria blood testing, more commonly 
through RDTs (69.7%) compared to malaria microscopy 
(44.2%) (Table  3). Malaria blooding testing was lowest 
among public health facilities in endemic areas (79.9%). 
Among all screened CHWs, availability of RDTs was 
4.3% and was highest in the endemic areas (7.3%) and 
endemic-prone areas (8.0%), compared to the seasonal-
transmission areas and low-risk areas where availability 
was less than 1%.
Table 2 Availability of anti-malarials in the public sector, 
among all screened outlets
a Endemic, N = 182; Endemic-prone, N = 246; Low-risk, N = 151; Seasonal-
transmission, N = 217
b Endemic, N = 682; Endemic-prone, N = 312; Low-risk, N = 316; Seasonal-
transmission, N = 505
Public Health  Facilitya CHWb
% (95% CI) % (95% CI)
Any anti-malarial
 Total 91.8 (89.2, 93.8) 2.4 (0.9, 6.3)
 Endemic 99.0 (95.8, 99.8) 4.2 (1.0, 15.6)
 Endemic-prone 97.6 (91.9, 99.3) 3.5 (0.8, 14.9)
 Low-risk 81.0 (72.2, 87.5) 0.0 (–)
 Seasonal-transmission 91.5 (86.5, 94.7) 0.7 (0.2, 2.2)
QAACT
 Total 87.1 (83.0, 90.4) 2.4 (0.9, 6.3)
 Endemic 92.2 (77.8, 97.6) 4.2 (1.0, 15.6)
 Endemic-prone 93.5 (85.0, 97.3) 3.5 (0.8, 14.9)
 Low-risk 77.0 (66.1, 85.2) 0.0 (–)
 Seasonal-transmission 87.5 (80.1, 92.4) 0.7 (0.2, 2.2)
Non-QAACT
 Total 12.3 (7.9, 18.7) 0.1 (0.0, 0.3)
 Endemic 9.3 (3.4, 22.9) 0.1 (0.0, 0.7)
 Endemic-prone 10.7 (5.1, 20.8) 0.1 (0.0, 1.2)
 Low-risk 17.8 (7.2, 37.9) 0.0 (–)
 Seasonal-transmission 10.8 (4.2, 25.2) 0.0 (–)
SP
 Total 17.6 (13.7, 22.3) 0.0 (–)
 Endemic 70.0 (56.4, 80.8) 0.0 (–)
 Endemic-prone 0.4 (0.0, 3.2) 0.0 (–)
 Low-risk 0.1 (0.0, 0.6) 0.0 (–)
 Seasonal-transmission 0.0 (–) 0.0 (–)
Artesunate IV/IM
 Total 46.0 (39.7, 52.3) 0.0 (–)
 Endemic 59.8 (41.6, 75.7) 0.0 (–)
 Endemic-prone 63.9 (50.9, 75.2) 0.0 (–)
 Low-risk 16.0 (6.8, 33.4) 0.0 (–)
 Seasonal-transmission 48.9 (39.3, 58.7) 0.0 (–)
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Among all screened public health facilities, 78.3% 
had both QAACT medicines and malaria blood test-
ing available, and this varied by epidemiological zone: 
endemic areas (75.6%), endemic-prone areas (84.6%), 
seasonal-transmission areas (72.8%) and low-risk areas 
(81.4%) (Table 4). Only 8.8% of public health facilities had 
QAACT medicines available but no malaria blood test-
ing, and this was highest in the endemic areas (16.7%).
Private sector availability
Among all screened private sector outlets, availability 
of any anti-malarial varied by facility type: private-for-
profit facilities (76.4%), registered pharmacies (93.3%), 
un-registered pharmacies (87.2%), and general retailers 
(2.4%) (Table  5). Among the anti-malarial stocking pri-
vate sector outlets 46.7% had QAACT medicines, and 
this was highest among registered pharmacies (73.2%) 
and lowest among general retailers (9.9%). Private sector 
availability of QAACT medicines also varied by epide-
miological zone: endemic areas (66.7%), endemic-prone 
areas (43.0%), seasonal-transmission areas (33.8%) and 
low-risk areas (42.2%) (Additional file  3). Availability of 
non-QAACT medicines was 37.9% in the private sec-
tor, and highest among anti-malarial stocking regis-
tered pharmacies (76.8%). Non-artemisinin therapy was 
stocked by 69.6% of the private sector and this was most 
commonly SP (57.6%). SP availability varied by outlet 
type, from 25.6% of private-for-profit facilities to 85.2% of 
general retailers.
The availability of diagnostic testing among anti-
malarial-stocking private sector outlets was 20.8% (12.4% 
malaria microscopy and 12.4% RDT), and varied by out-
let type: private for–profit facilities (66.9%), registered 
pharmacies (22.4%), unregistered pharmacies (12.1%) 
and general retailers (0.2%).
Anti‑malarial market share
Figure  1 illustrates the anti-malarial market share (the 
amount of anti-malarials sold or distributed during the 
week preceding the survey) across the public and private 
sector, according to outlet type and by anti-malarial. In 
total, 70.6% of anti-malarials were distributed through 
the private sector. Most of the private sector distribution 
was through unregistered pharmacies (37.3%) followed 
by private for-profit health facilities (13.4%), registered 
pharmacies (12.8%) and general retailers (7.1%). Anti-
malarial market share for the public sector was 29.4% and 
nearly all treatments distributed were QAACT medicines 
(25.6%). Within the private sector, 32.5% of the market 
share was accounted for by QAACT medicines, followed 
by non-QAACT medicines (15.0%) and non-artemisinin 
therapy (27.2%), which was typically SP (22.1%).
The private-sector market share of all anti-malarials 
varied across epidemiological zones (Fig.  2): endemic 
areas (59.2%), endemic-prone areas (68.8%), sea-
sonal-transmission areas (81.8%) and low-risk areas 
(94.9%). QAACT medicines market share was highest 
Table 3 Availability of malaria diagnostic testing in the 
public sector, among all screened outlets
a Endemic, N = 182; Endemic-prone, N = 246; Low-risk, N = 151; Seasonal-
transmission, N = 217
b Endemic, N = 682; Endemic-prone, N = 312; Low-risk, N = 316; Seasonal-
transmission, N = 505
Public Health  Facilitya CHWb
% (95% CI) % (95% CI)
Any diagnostic test
 Total 86.4 (82.4, 89.6) 4.3 (2.2, 8.2)
 Endemic 79.9 (68.8, 87.8) 7.3 (3.1, 16.2)
 Endemic-prone 89.9 (84.7, 93.4) 8.0 (2.2, 24.8)
 Low-risk 88.4 (77.1, 94.5) 0.0 (–)
 Seasonal-transmission 87.6 (82.5, 91.4) 0.4 (0.1, 1.6)
Microscopy
 Total 44.2 (40.1, 48.4) 0.1 (0.0, 0.4)
 Endemic 48.3 (41.2, 55.5) 0.0 (–)
 Endemic-prone 47.0 (39.0, 55.2) 0.0 (–)
 Low-risk 45.7 (36.3, 55.5) 0.0 (–)
 Seasonal-transmission 36.8 (28.4, 46.1) 0.2 (0.0, 1.6)
RDT
 Total 69.7 (62.8, 75.9) 4.3 (2.2, 8.2)
 Endemic 57.3 (40.7, 72.4) 7.3 (3.1, 16.2)
 Endemic-prone 69.9 (60.3, 78.1) 8.0 (2.2, 24.8)
 Low-risk 80.5 (65.7, 89.8) 0.0 (–)
 Seasonal-transmission 70.5 (57.9, 80.6) 0.4 (0.1, 1.6)
Table 4 Readiness for malaria case management in the 
public sector, among all screened outlets
a Endemic, N = 182; Endemic-prone, N = 246; Low-risk, N = 151; Seasonal-
transmission, N = 217
b Endemic, N = 682; Endemic-prone, N = 312; Low-risk, N = 316; Seasonal-
transmission, N = 505
Public Health  Facilitya CHWb
% (95% CI) % (95% CI)
QAACT and malaria testing available
 Total 78.3 (73.6, 82.4) 1.9 (0.7, 4.9)
 Endemic 75.6 (61.9, 85.5) 3.2 (0.8, 11.8)
 Endemic-prone 84.6 (76.5, 90.3) 3.3 (0.7, 13.9)
 Low-risk 72.8 (61.6, 81.7) 0.0 (-)
 Seasonal-transmission 81.4 (73.1, 87.5) 0.4 (0.1, 1.6)
QAACT available but no malaria testing available
 Total 8.8 (6.2, 12.3) 0.5 (0.2, 1.7)
 Endemic 16.7 (9.2, 28.3) 1.0 (0.2, 4.7)
 Endemic-prone 8.8 (5.6, 13.7) 0.3 (0.0, 2.3)
 Low-risk 4.2 (1.5, 11.7) 0.0 (-)
 Seasonal-transmission 6.1 (3.4, 10.7) 0.3 (0.1, 1.8)
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Table 5 Availability of malaria commodities in the private sector
Among outlets stocking anti-malarials todays or within the past 3 months
Private For‑Profit Facility Registered pharmacy Unregistered pharmacy General retailer Total private sector
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Availability of anti-malar-
ials among all screened 
outlets
N = 360 N = 145 N = 493 N = 14,204 N = 15,202
 Any anti-malarial 76.4 93.3 87.2 2.4 7.1
(70.4, 81.4) (87.8, 96.5) (82.8, 90.6) (1.7, 3.5) (6.4, 7.9)
Availability of anti-malarials 
among anti-malarial-
stocking outlets
N = 280 N = 134 N = 428 N = 244 N = 1086
 QAACT 59.3 73.2 64.3 9.9 46.7
(51.2, 67.0) (65.6, 79.7) (58.6, 69.7) (5.1, 18.4) (39.4, 54.1)
 Non-QAACT 52.3 76.8 48.5 3.0 37.9
(44.6, 59.9) (68.7, 83.3) (41.4, 55.6) (1.3, 6.8) (31.5, 44.7)
 SP 25.6 49.9 55.2 85.2 57.6
(19.5, 32.9) (38.9, 61.0) (47.1, 63.0) (75.1, 91.6) (50.8, 64.0)
 Any non-artemisinin 
therapy
50.3 57.2 68.7 88.5 69.6
(42.8, 57.8) (45.1, 68.4) (60.6, 75.8) (78.9, 94.1) (63.2, 75.4)
 Artesunate injection 10.1 1.7 1.2 0.0 2.9
(5.9, 16.8) (0.5, 5.6) (0.5, 2.6) – (1.7, 4.7)
Availability of blood testing 
among anti-malarial-
stocking  outletsa
N = 307 N = 138 N = 467 N = 310 N = 1222
 Any diagnostic test 66.9 22.4 12.1 0.2 20.8
(59.2, 73.8) (16.4, 29.8) (9.1, 16.0) (0.0, 1.4) (16.5, 25.8)
 Malaria microscopy 48.1 8.8 3.2 0.0 12.4
(39.1, 57.3) (5.0, 15.1) (2.0, 5.3) – (9.1, 16.7)
 RDT 36.0 16.0 9.5 0.2 12.6
(30.2, 42.3) (11.1, 22.5) (7.0, 13.0) (0.0, 1.4) (10.0, 15.8)
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in endemic areas where (74.9% of anti-malarials dis-
tributed were QAACT), and lower in other zones: 
endemic-prone areas (49.4%), seasonal-transmission 
areas (32.2%) and low-risk areas (37.9%). Market share 
for non-QAACT medicines was lowest in endemic 
areas (9.7%) and highest in low-risk areas (24.8%). SP 
market share was 14.2% in endemic areas, 27.5% in 
endemic-prone areas, 45.7% in seasonal-transmission 
areas and 33.9% in low-risk areas. SP was exclusively 
distributed by the private sector in endemic-prone and 
low-risk areas, and mostly by the private sector in sea-
sonal-transmission areas (0.3% of the public sector and 
45.4% of the private sector).
Malaria blood testing market share
Figure 3 shows that 66.9% of malaria blood testing was 
performed in the public sector and within the sector the 
market share of malaria microscopy (35.6%) and RDTs 
(31.3%) was comparable. A third (33.1%) of blood test-
ing market share was delivered through private sec-
tor outlets and testing was more commonly performed 
through malaria microscopy (21.6%) than RDTs (11.5%). 
Notably, majority of the private sector malaria tests were 
delivered primarily by private-for-profit health facili-
ties (28.5%) and was rare among registered pharmacies 
(2.2%), unregistered pharmacies (2.4%) and general 
retailers (0%).
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Private sector price for malaria treatments and blood 
testing
Table  6 summarizes the private sector median price for 
anti-malarials and blood testing. The median retail price 
for one QAACT AETD was $1.31 (IQR: 1.00–1.51). Non-
QAACT AETD was $3.52 (IQR: 1.51–5.02). The median 
price for a SP AETD was $0.45 (IQR: 0.30–0.50) (Table 6).
In regard to the cost of malaria blood testing, an adult 
patient was required to pay a median cost $1.00 to receive 
a malaria test using microscopy (IQR: 0.50–1.51) or RDT 
(IQR: 1.00–1.00). Similarly, the price of testing for chil-
dren, either with microscopy or RDT, was $1.00 [micros-
copy (IQR: 0.50–100) or RDT (IQR: 0.50–100)].
Provider perceptions of the most effective treatment 
for uncomplicated malaria
Figure  4 illustrates the extent to which providers per-
ceived ACT as the most effective treatment for uncom-
plicated malaria in an adult. Nearly all providers (96.3%) 
in the public sector perceived ACT as the most effective 
treatment for uncomplicated malaria for adults. In the 
private sector, 64.1% perceived ACT to be the most effec-
tive, 16.4% perceived SP as the most effective, 9.2% cited 
another anti-malarial, and 10.2% did not know. General 
retailers and unregistered pharmacy providers were the 
most common outlet types to cite an anti-malarial other 
than an ACT or to report that they did not know what 
was the most effective treatment for malaria in an adult 
(81.1 and 14.8%, respectively). With regards to percep-
tions of the most effective anti-malarial for a child, a sim-
ilar pattern was observed: 95.3% public sector cited an 
ACT, versus only 61.2% of private providers (Additional 
file 4).
Discussion
This study provided a complete picture of the malaria 
testing and treatment landscape across public and private 
sectors in Kenya in 2016. Findings suggest that public 
sector readiness to test and appropriately treat malaria 
in Kenya is relatively high, but there is gap in availability 
of both testing and treatment that must be addressed in 
order to achieve universal coverage. In the private sector, 
where the majority of anti-malarials are distributed, the 
extent to which providers have malaria testing and appro-
priate anti-malarial medicines available is sub-optimal. 
These findings in combination with results from previous 
survey rounds, and current evidence from the different 
epidemiological zones, point to the progress which has 
been achieved as well as recommendations for improving 
malaria case management in Kenya.
Public sector readiness to test and treat for malaria
Previous ACTwatch studies have demonstrated high avail-
ability of QAACTs and malaria blood testing since 2010 
and 2014 respectively [16]. Nonetheless in 2016, one in 
Table 6 Median private sector price
N Median Interquartile range
Median price of a tablet AETD
 QAACT 741 $1.31 1.00–1.51
 Non-QAACT 845 $3.52 1.51–5.02
 SP 768 $0.45 0.30–0.50
Median price of one test
 Malaria microscopy for an adult 204 $1.00 0.50–1.51
 Malaria microscopy for a child 203 $1.00 0.50–100
 Malaria RDT for an adult 179 $1.00 1.00–1.00
 Malaria RDT for a child 178 $1.00 0.50–1.00
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five public health facilities did not have both QAACT and 
malaria blood testing available, pointing to the need to 
close this gap in order to achieve universal coverage. Fur-
thermore, while availability of QAACT was generally high, 
the implementation of the AL policy includes delivery of 
four different AL pack sizes (6, 12, 18 and 24 tablets) suit-
able for management of four different weight categories of 
patients. Availability of the different weight categories was 
more variable among public health facilities, with less than 
40% of outlets having the 18 tablet pack size in stock. Only 
half of the public health facilities stocked treatment for 
severe malaria, injectable artesunate, and this was similar 
to levels in 2014 [18]. SP for IPTp was available in 70% of 
public health facilities in endemic areas where it is recom-
mended for IPTp, and rarely found among public health 
facilities outside of the endemic areas, illustrating align-
ment with national guidelines in these areas.
Some of the gaps found among public health facilities 
may be explained by changes in the supply and distribution 
of anti-malarial medicines and RDTs in the public sector. 
The Government of Kenya transitioned from a traditional 
central medical store using a push-distribution system 
to a pull-distribution system for malaria commodities, 
through the Kenya Medical Supplies Agency (KEMSA). 
However, the role of KEMSA to provide health commodi-
ties according to the requested needs (“pull” system) rather 
than allocated proportions of the total supply (“push” sys-
tem) presented a number of challenges [16], and resulted 
in frequent stock-outs and erratic supplies of commodi-
ties to public health facilities. This has been attributed to 
limited capacity to quantify needs, insufficient budget, and 
challenges in maintaining a full pipeline of commodities 
to meet county specific needs [5]. As a means to prevent 
irrational anti-malarial medicines and RDT procurements 
and stock-outs within the public sector, more recently the 
National Malaria Control Programme and KEMSA have 
implemented a “smart push” system for malaria commodi-
ties. This strategy sets limits on the maximum quantity 
of malaria commodities that can be supplied to a facil-
ity, depending on the level of care and the epidemiologi-
cal area. This strategy may help to further close the gap 
in availability of both testing and treatment in the public 
sector and will be important to safeguard the gains made 
nationally in malaria case management.
The reach of the public sector has been extended to 
the community-level through the training and equip-
ping of CHW with malaria case management skills and 
supplies in endemic areas since 2012 [3]. The findings 
illustrate that a small portion of CHWs were ready for 
malaria case management and these were restricted to 
endemic and endemic-prone areas where interventions 
are being piloted. Low levels of QAACT and RDT avail-
ability even within these areas may be explained by the 
lack of a consistent public sector malaria commodity 
supply as previously discussed. Changes to the supply 
and distribution of anti-malarial medicines in the pub-
lic sector has been described as contributing to delays 
in implementation of the malaria CHW strategy as pub-
lic health facilities were either reluctant to give limited 
malaria commodities to CHWs or had no commodities 
to supply CHWs [5]. Maintaining a network of trained 
and equipped CHWs will be central to ensuring access 
to malaria case management services in rural areas. Key 
challenges to be addressed include gaps in CHW moti-
vation and retention, training and maintaining supervi-
sion [17].
The role of the private sector
Consistent with previous studies [18], the private sec-
tor plays an important role in malaria case management 
given almost three-fourths of all anti-malarials were dis-
tributed through this sector. While unregistered pharma-
cies comprised most of the market share, other private 
facilities also contributed to the anti-malarial distribu-
tion, including general retailers. As national policy stip-
ulates that only private for-profit health facilities and 
registered pharmacies are licensed to sell medications, 
the results from this study suggest many anti-malarial 
medicines are being distributed through unregulated 
sources. Indeed, the Kenya Pharmacy and Poisons Board 
stipulates that for outlets to legally administer medi-
cines, including anti-malarials, they must be registered 
with the board. In addition, medicines may only be dis-
pensed under the supervision of a certified pharmacist 
or pharmaceutical technologists [19]. However, given 
the widespread distribution of anti-malarials through 
unregistered pharmacies and general retailers, strategies 
are needed to engage with these outlet types. One option 
may be to permit the licensing of unregistered pharma-
cies through accreditation programmes, or through part-
nerships with the public sector, as a means to increase 
access to appropriate malaria case management services. 
Evidence from other countries has demonstrated that 
the registration, training and supervision of the private 
sector, can lend to improvements in malaria commodity 
ACT availability, distribution and provider performance 
[20–23].
Private sector readiness to test and treat for malaria
Among private sector outlets in the business of anti-
malarial distribution, fewer than half had QAACT avail-
able in 2016, reflecting a decrease from levels reported 
in 2011 (60%) and 2014 (71%) [18]. Although the private 
sector CPM for QAACT administered by the Global 
Fund continued through 2016 in Kenya, important 
changes and challenges in the post-pilot period are likely 
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to have contributed to the decline in availability. Since 
the AMFm, Kenya transitioned from a dedicated donor 
funding to a country specific grant funding mechanism, 
which was further amplified by a reduction in fund-
ing for co-paid ACTs. Indeed, the number of subsidized 
QAACT doses delivered to Kenya’s private sector in 2015 
through the CPM was half of what it was in 2012 [9]. 
In this context, lower availability of QAACT in the pri-
vate sector as compared to previous rounds can largely 
be explained by a more limited supply and availability of 
these anti-malarials given reduced funding.
Only one in five private providers stocking anti-malar-
ial medicines had confirmatory testing available and this 
was highest among private for-profit facilities, reflect-
ing national policy which only permits these types of 
facilities to administer confirmatory testing. While the 
private sector distributed the majority of anti-malarial 
medicines, only one-third of malaria blood tests were 
performed by private outlets, suggesting that presump-
tive treatment is common. Permitting other private sec-
tor outlet types to administer diagnostic testing may be 
one means to increase access to confirmatory testing as 
evidenced by a number of private sector RDT pilot initia-
tives [24–26]. Studies from Kenya have shown that reg-
istered pharmacies participating in a RDT pilot almost 
always correctly managed negative patients as per the 
government recommended treatment algorithm [11]. In 
addition, there were few differences in the performance 
of pharmacies and private for-profit health facilities, 
lending to the author’s conclusion that malaria diagnosis 
through RDTs can take place safely and effectively across 
a variety of channels. Given the role of unregistered 
pharmacies in Kenya, these facilities in particular may be 
critical to increasing access to confirmatory testing prior 
to treatment, though future research is merited to assess 
the feasibility of introducing RDTs among these outlet 
types. This is particularly pertinent as Kenya is deciding 
whether to legalize and/or subsidize RDTs in registered 
pharmacies as part of its malaria control strategy.
Market share
Most of the anti-malarial market share comprised of 
QAACT, while one in four anti-malarials distributed were 
SP—and most commonly distributed through the private 
sector. Market share for QAACT was highest in endemic 
areas as compared with other epidemiological areas 
where distribution of SP was relatively common. In sea-
sonal-transmission areas, SP accounted for nearly half of 
all anti-malarial distribution with nearly all of these treat-
ments going through the private sector. SP accounted for 
about one-third of anti-malarials distributed in endemic-
prone and low-risk areas. This finding suggests that SP 
is being used for malaria case management within the 
private sector and outside of endemic areas and points 
to the need to ensure continued availability of affordable 
QAACT in the private sector across the country, and not 
just focused in endemic areas. Furthermore, these find-
ings suggest that unless effective private sector strategies 
are identified and implemented, further decline in private 
sector availability may be observed. In absence of subop-
timal private sector engagement and support, and social 
and behaviour change communication for providers and 
consumers to raise awareness of QAACT, Kenya may see 
an increasing market share for SP.
Several reasons may explain the ongoing distribution 
of SP for case management. This may be in part driven 
by price as QAACT was approximately three times more 
expensive than SP in the private sector. While the price 
of SP has remained consistently low since 2010, the price 
of QAACT has fluctuated, initially dropping to nearly the 
same price as SP in 2011 but then increasing by 2014 [18]. 
The persistence of inexpensive SP may inhibit the uptake 
of QAACT even with a subsidy mechanism in place, and 
especially in the context of a reduced subsidy since the 
AMFm period. Furthermore, in the absence of support-
ive interventions to increase awareness of subsidized 
ACT (which ceased in 2015), providers and consumers 
may have less awareness of the subsidized ACT medi-
cine. Indeed, the results also illustrate how some pri-
vate sector providers perceived non-ACT medicines as 
the most effective treatment for uncomplicated malaria. 
Finally, while availability of QAACT was low in the pri-
vate sector, the data also illustrate how there was vari-
ability according to different pack sizes, perhaps causing 
providers to ration ACTs. Other evidence has suggested 
that providers will administer other artemisinin therapies 
over ACT if supply is uncertain and availability is lower 
than non-recommended treatments [27]. Additional 
research to understand provider and consumer practices 
and demand for SP will be valuable to provide insights 
into the ongoing distribution.
Nearly one in five anti-malarials distributed were 
non-QAACTs. Non-QAACT was about 2.5 times more 
expensive than QAACT in the private sector. This raises 
the question of why consumers would pay more for non-
QAACT when less expensive QAACT are available? 
Other ACTwatch research has shown that non-QAACT 
products were primarily distributed by pharmacies and 
drug stores in urban areas of Kenya. Thus the distribution 
of non-QAACT may reflect a higher purchasing power of 
urban consumers [28]. More research is needed to under-
stand the reason for provider dispensing practices of 
non-QAACT as well as consumer preferences. Address-
ing the availability and distribution of non-QAACT will 
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also require addressing elements of the supply chain, as 
well a product registration, manufacturing, importation 
laws and regulation.
Limitations
General limitations of the study design which are appli-
cable to all ACTwatch outlet surveys have been described 
in detail elsewhere [12, 14, 29]. In particular, the study is 
descriptive in nature and the results are unable to provide 
analytical information on the causal effects of interven-
tions on the malaria testing and diagnostic landscape.
Conclusions
Although public sector readiness to test and appropri-
ately treat malaria in Kenya is relatively high, there is a 
gap in availability of both testing and treatment that must 
be addressed in order to achieve universal coverage. Also 
critical to achieving universal coverage with appropri-
ate malaria case management in Kenya is the private sec-
tor, where the majority of anti-malarials are distributed. 
This includes distribution of nearly half of all anti-malarial 
medicines by unregistered and unregulated pharmacies 
and general retail outlets. There is need for strategies to 
effectively engage or regulate these outlet types. While pri-
vate sector readiness to treat malaria according to national 
guidelines improved with a large scale QAACT subsidy 
piloted under the AMFm, availability of QAACT has sub-
sequently declined to less than half of anti-malarial stock-
ing private sector outlets in 2016. Given the continued role 
of the private sector in anti-malarial distribution, there is 
need for a renewed commitment and effective strategies to 
ensure access to affordable QAACT in the private sector. 
Additionally, given the aim of confirmatory testing prior to 
treatment, the low availability of testing particularly among 
the unregistered pharmacies, suggests need to examine 
policies and strategies for private sector malaria testing.
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